A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 5, 2013, Pages 2029-2035

  Tejman Yarden, Noa ^a   Miyamoto, Yukiko ^a   Leitsch, David ^a   Santini, Jennifer ^a   Debnath, Anjan ^b   Gut, Jiri ^b   McKerrow, James H ^b   Reed, Sharon L ^a,c   Eckmann, Lars ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c University of California at San Francisco   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMINOACRIDINE; ASTEMIZOLE; AURANOFIN; BAZEDOXIFENE; BRILLIANT GREEN; CETYLPYRIDINIUM SALT; CHLORQUINALDOL; DISULFIRAM; DOCETAXEL; EBASTINE; EMETINE; FENBENDAZOLE; FURAZOLIDONE; GENISTEIN; HARRINGTONINE; METERGOLINE; METRONIDAZOLE; NOCODAZOLE; OXFENDAZOLE; PERHEXILINE; PICLAMILAST; PODOPHYLLOTOXIN; PUROMYCIN; ROXARSONE; SECNIDAZOLE; TIABENDAZOLE; TINIDAZOLE; UNINDEXED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; GIARDIA LAMBLIA; GIARDIASIS; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIRHEUMATIC AGENTS; AURANOFIN; DRUG REPOSITIONING; DRUG RESISTANCE; DYSENTERY; ENZYME INHIBITORS; GERBILLINAE; GIARDIA LAMBLIA; GIARDIASIS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; METRONIDAZOLE; MICE; OXIDATIVE STRESS; OXIDOREDUCTASES; SMALL MOLECULE LIBRARIES; THIOREDOXINS;

EID: 84875625471     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01675-12     Document Type: Article

References (42)

1. Savioli L, Smith H, Thompson A. 2006. Giardia and Cryptosporidium join the 'Neglected Diseases Initiative'. Trends Parasitol. 22:203-208.
2. Wensaas KA, Langeland N, Hanevik K, Morch K, Eide GE, Rortveit G. 2012. Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study. Gut 61:214-219.
3. Gardner TB, Hill DR. 2001. Treatment of giardiasis. Clin. Microbiol. Rev. 14:114-128.
4. Tejman-Yarden N, Millman M, Lauwaet T, Davids BJ, Gillin FD, Dunn L, Upcroft JA, Miyamoto Y, Eckmann L. 2011. Impaired parasite attachment as fitness cost of metronidazole resistance in Giardia lamblia. Antimicrob. Agents Chemother. 55:4643-4651.
5. Escobedo AA, Cimerman S. 2007. Giardiasis: a pharmacotherapy review. Expert Opin. Pharmacother 8:1885-1902.
6. Upcroft P, Upcroft JA. 2001. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin. Microbiol. Rev. 14:150-164.
7. Wright JM, Dunn LA, Upcroft P, Upcroft JA. 2003. Efficacy of antigiardial drugs. Expert Opin. Drug Saf. 2:529-541.
8. Chen CZ, Kulakova L, Southall N, Marugan JJ, Galkin A, Austin CP, Herzberg O, Zheng W. 2011. High-throughput Giardia lamblia viability assay using bioluminescent ATP content measurements. Antimicrob. Agents Chemother. 55:667-675.
9. Gut J, Ang KK, Legac J, Arkin MR, Rosenthal PJ, McKerrow JH. 2011. An image-based assay for high throughput screening of Giardia lamblia. J. Microbiol. Methods 84:398-405.
10. Debnath A, Parsonage D, Andrade RM, He C, Cobo ER, Hirata K, Chen S, Garcia-Rivera G, Orozco E, Martinez MB, Gunatilleke SS, Barrios AM, Arkin MR, Poole LB, McKerrow JH, Reed SL. 2012. A highthroughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat. Med. 18:956-960.
11. Boreham PF, Upcroft J, Upcroft P, Andrews R. 1988. Zoonotic Giardia - the debate goes on. Parasitol. Today 4:322.
12. Townson SM, Laqua H, Upcroft P, Boreham PF, Upcroft JA. 1992. Induction of metronidazole and furazolidone resistance in Giardia. Trans. R. Soc. Trop. Med. Hyg. 86:521-522.
13. Dunn LA, Burgess AG, Krauer KG, Eckmann L, Vanelle P, Crozet MD, Gillin FD, Upcroft P, Upcroft JA. 2010. A new-generation 5-nitroimidazole can induce highly metronidazole-resistant Giardia lamblia in vitro. Int. J. Antimicrob. Agents 36:37-42.
14. Upcroft JA, Boreham PF, Campbell RW, Shepherd RW, Upcroft P. 1995. Biological and genetic analysis of a longitudinal collection of Giardia samples derived from humans. Acta Trop. 60:35-46.
15. Valdez CA, Tripp JC, Miyamoto Y, Kalisiak J, Hruz P, Andersen YS, Brown SE, Kangas K, Arzu LV, Davids BJ, Gillin FD, Upcroft JA, Upcroft P, Fokin VV, Smith DK, Sharpless KB, Eckmann L. 2009. Synthesis and electrochemistry of 2-ethenyl and 2-ethanyl derivatives of 5-nitroimidazole and antimicrobial activity against Giardia lamblia. J. Med. Chem. 52:4038-4053.
16. Leitsch D, Burgess AG, Dunn LA, Krauer KG, Tan K, Duchene M, Upcroft P, Eckmann L, Upcroft JA. 2011. Pyruvate:ferredoxin oxidoreductase and thioredoxin reductase are involved in 5-nitroimidazole activation while flavin metabolism is linked to 5-nitroimidazole resistance in Giardia lamblia. J. Antimicrob. Chemother. 66:1756-1765.
17. Farthing MJ, Inge PM, Pearson RM. 1987. Effect of D-propranolol on growth and motility of flagellate protozoa. J. Antimicrob. Chemother. 20:519-522.
18. Angelucci F, Sayed AA, Williams DL, Boumis G, Brunori M, Dimas trogiovanni D, Miele AE, Pauly F, Bellelli A. 2009. Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: structural and kinetic aspects. J. Biol. Chem. 284:28977-28985.
19. Jackson-Rosario S, Cowart D, Myers A, Tarrien R, Levine RL, Scott RA, Self WT. 2009. Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au-Se adduct. J. Biol. Inorg Chem. 14:507-519.
20. Gottlieb NL. 1986. Pharmacology of auranofin: overview and update. Scand. J. Rheumatol. Suppl. 63:19-28.
21. Hudson AL, Sotirchos IM, Davey MW. 2010. Substrate specificity of the mitochondrial thioredoxin reductase of the parasitic nematode Haemonchus contortus. Parasitol. Res. 107:487-493.
22. Gromer S, Arscott LD, Williams CH, Jr, Schirmer RH, Becker K. 1998. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J. Biol. Chem. 273:20096-20101.
23. Leitsch D, Kolarich D, Duchene M. 2010. The flavin inhibitor diphenyleneiodonium renders Trichomonas vaginalis resistant to metronidazole, inhibits thioredoxin reductase and flavin reductase, and shuts off hydrogenosomal enzymatic pathways. Mol. Biochem. Parasitol. 171:17-24.
24. Kean WF, Hart L, Buchanan WW. 1997. Auranofin. Br. J. Rheumatol. 36:560-572.
25. Kean WF, Kean IR. 2008. Clinical pharmacology of gold. Inflammopharmacology 16:112-125.
26. Lobanov AV, Gromer S, Salinas G, Gladyshev VN. 2006. Selenium metabolism in Trypanosoma: characterization of selenoproteomes and identification of a Kinetoplastida-specific selenoprotein. Nucleic Acids Res. 34:4012-4024.
27. Brown DM, Upcroft JA, Edwards MR, Upcroft P. 1998. Anaerobic bacterial metabolism in the ancient eukaryote Giardia duodenalis. Int. J. Parasitol. 28:149-164.
28. Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J, Arner ES, Williams DL. 2007. Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med. 4:e206. doi:10.1371/journal.pmed.0040206.
29. Chopra S, Torres-Ortiz M, Hokama L, Madrid P, Tanga M, Mortelmans K, Kodukula K, Galande AK. 2010. Repurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 65:2598-2601.
30. Chopra S, Matsuyama K, Hutson C, Madrid P. 2011. Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae. J. Antimicrob. Chemother. 66:1533-1536.
31. Nash T, Rice WG. 1998. Efficacies of zinc-finger-active drugs against Giardia lamblia. Antimicrob. Agents Chemother. 42:1488-1492.
32. Edlind TD, Hang TL, Chakraborty PR. 1990. Activity of the anthelmintic benzimidazoles against Giardia lamblia in vitro. J. Infect. Dis. 162:1408-1411.
33. Sandhu H, Mahajan RC, Ganguly NK. 2004. Flowcytometric assessment of the effect of drugs on Giardia lamblia trophozoites in vitro. Mol. Cell. Biochem. 265:151-160.
34. Alanis AD, Calzada F, Cedillo-Rivera R, Meckes M. 2003. Antiprotozoal activity of the constituents of Rubus coriifolius. Phytother. Res. 17:681-682.
35. Morgan UM, Reynoldson JA, Thompson RC. 1993. Activities of several benzimidazoles and tubulin inhibitors against Giardia spp. in vitro. Antimicrob. Agents Chemother. 37:328-331.
36. Khan IA, Avery MA, Burandt CL, Goins DK, Mikell JR, Nash TE, Azadegan A, Walker LA. 2000. Antigiardial activity of isoflavones from Dalbergia frutescens bark. J. Nat. Prod. 63:1414-1416.
37. Singer SM, Yee J, Nash TE. 1998. Episomal and integrated maintenance of foreign DNA in Giardia lamblia. Mol. Biochem. Parasitol. 92:59-69.
38. Lim KS, Kam PC. 2008. Chlorhexidine - pharmacology and clinical applications. Anaesthesia Intensive Care 36:502-512.
39. Mao X, Schimmer AD. 2008. The toxicology of Clioquinol. Toxicol. Lett. 182:1-6.
40. Mogi T, Kita K. 2009. Gramicidin S and polymyxins: the revival of cationic cyclic peptide antibiotics. Cell. Mol. Life Sci. 66:3821-3826.
41. Guthery E, Seal LA, Anderson EL. 2005. Zinc pyrithione in alcohol-based products for skin antisepsis: persistence of antimicrobial effects. Am. J. Infect. Control 33:15-22.
42. Chung KT, Wong TY, Wei CI, Huang YW, Lin Y. 1998. Tannins and human health: a review. Crit. Rev. Food Sci. Nutr. 38:421-464